Peptic Ulcer Disease (PUD): An overview of the History, Risk factors, Symptoms, Diagnosis Considerations and Conventional Management


  • Mohd. Shahid Khan Department of Pharmacy, Lords University, Alwar (Rajasthan)
  • Vijay Singh Principal, Department of Pharmacy, Lords University, Alwar (Rajasthan)
  • Pankaj Arora Faculty of Pharmaceutical Sciences, Lords University, Alwar (Rajasthan)



PUD, Risk factors, H. Pylori, PPIs, Resistance


Gastric and duodenal ulcer (PUD), are upper gastrointestinal disorders sharing a common abnormality, too much acid and pepsin activity followed by inflammation, necrosis and ulceration of exposed mucosa. H. Pylori infection, use of NSAIDs and stress are the major risk factors that lead to the occurrence of PUD. With the introduction of proton pump inhibitors (PPIs) and antibiotics against H. Pylori resolution of symptom and rapid ulcer healing was obtained but cure of PUD has failed. However, new challenges have emerged due to increasing antibiotic resistance of H. pylori. Management of peptic ulcer needs accurate identification of the ulcerogenic cause in the individual patient for proper selection of therapy.



Download data is not yet available.

Author Biographies

Mohd. Shahid Khan, Department of Pharmacy, Lords University, Alwar (Rajasthan)

Research Scholar, Department of Pharmacy, Lords University, Alwar (Rajasthan)

Vijay Singh, Principal, Department of Pharmacy, Lords University, Alwar (Rajasthan)

Principal, Department of Pharmacy, Lords University, Alwar (Rajasthan)

Pankaj Arora, Faculty of Pharmaceutical Sciences, Lords University, Alwar (Rajasthan)

Faculty of Pharmaceutical Sciences, Lords University, Alwar (Rajasthan)


1. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007; 11(51):3-164.
2. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician. 2007; 76(7):1005-12.
3. Pasina L, Nobili A, Tettamanti M, etal. REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22:205-10. 10.1016/j.ejim.2010.11.009 21402255
4. Lanas A, Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis 2015; 74:675-81.
5. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29:938-46. 10.1111/j.1365-2036.2009. 03960. x 19220208
6. Werdmuller BF, van der Putten AB, Loffeld RJ. The clinical presentation of peptic ulcer disease. Neth J Med 1997; 50:115-9. 10.1016/S0300-2977(96)00075-7 9121595
7. Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985; 142:439-44.3982346
8. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348: g3174. 10.1136/bmj. g3174 24846275
9. Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30:791-815. 10.1111/j.1365-2036.2009. 04105.x 19706147
10. Coblijn UK, Goucham AB, Lagarde SM, Kuiken SD, van Wagensveld BA. Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review. ObesSurg2014;24:299-309.10.1007/s11695-013-1118-5 24234733
11. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24:2-17. 10.1097/00004836-199701000-00002 9013343
12. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hallas J. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: a population-based case-control study. Aliment Pharmacol Ther 2010; 32:1383-91. 10.1111/j.1365-2036.2010. 04472.x 21050241
13. Jiang HY, Chen HZ, Hu XJ, etal . Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015;13:42-50.e3. 10.1016/j.cgh.2014.06.021 24993365
14. Krag M, Perner A, Wetterslev J, etal. SUP-ICU co-authors. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med 2015;41:833-45. 10.1007/s00134-015-3725-1 25860444
15. Tamura J, Arakaki S, Shibata D, Maeshiro T. Cytomegalovirus-associated gastric ulcer: a diagnostic challenge in a patient of fulminant hepatitis with steroid pulse therapy. BMJ Case Rep 2013;2013. 10.1136/bcr-2013-010501 23997079
16. Kurata JH, Haile BM. Epidemiology of peptic ulcer disease. Clin Gastroenterol. 1984 May; 13(2): 289–307.
17. Scheeres DE, Dekryger LL; Surgical treatment of peptic ulcers before and after the introduction of H2 blockers. Primary Care, 1987;53(7):392-397.
18. Svanes C, Soreide J, Skarstein A, Fevang B, Bakke P, Vollset S, Svanes K, Soreide O; Smoking and ulcer perforation. Gut, 1997;41(2):177-180.
19. Smedley FH, Hickish P; Nonsteroidalanti inflammatory drugs and perforation. Gut; 1986;27:114-120.
20. Thorsen K, Soreide JA, Soreide K. Long-term mortality in patients operated for perforated peptic ulcer: factors limiting longevity are dominated by older age, comorbidity burden and severe postoperative complications. World J Surg. 2017 Feb. 41(2):410-8.
21. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017; 112(2):212-39.
22. Early DS, Lightdale JR, Vargo JJ 2nd, et al, for the ASGE Standards of Practice Committee. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2018; 87(2):327-37.
23. National Institute for Health and Care Excellence. The management of dyspepsia in adult patients in primary care, guidelines from National Institute for Health and Clinical Excellence. London: NICE, 2004.
24. Saniee P, Shahreza S, Siavoshi F. Negative effect of proton-pump inhibitors (PPIs) on Helicobacter pylori growth, morphology, and urease test and recovery after PPI removal–an in vitro study. Helicobacter 2016; 21:143-52. 10.1111/hel.12246 26222264
25. Siddique, O.; Ovalle, A.; Siddique, A.S.; Moss, S.F. Helicobacter pylori infection: An update for the internist in the age of increasing global antibiotic resistance. Am. J. Med. 2018; 131:473–479
26. Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017, 66, 6–30.
27. Sun, Q.; Liang, X.; Zheng, Q.; Liu, W.; Xiao, S.; Gu, W.; Lu, H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15:233–238.
28. Chey, W.D.; Leontiadis, G.I.; Howden, C.W.; Moss, S.F. Acg clinical guideline: Treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 2017, 112, 212–239.
29. Chen, P.Y.; Wu, M.S.; Chen, C.Y.; Bair, M.J.; Chou, C.K.; Lin, J.T.; Liou, J.M.; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2016; 44:427–437.
30. Strand, D.S.; Kim, D.; Peura, D.A. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver 2017, 11, 27–37.
31. Da Costa Di Bonaventura, M.; Yuan, Y.; Wagner, J.S.; L’Italien, G.J.; Lescrauwaet, B.; Langley, P. The burden of viral hepatitis C in Europe: A propensity analysis of patient outcomes. Eur. J. Gastroenterol. Hepatol. 2012; 24:869–877.
32. Lambert, A.A.; Lam, J.O.; Paik, J.J.; Ugarte-Gil, C.; Drummond, M.B.; Crowell, T.A. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis. PLoS ONE 2015, 10, e0128004.
33. Kwok, C.S.; Arthur, A.K.; Anibueze, C.I.; Singh, S.; Cavallazzi, R.; Loke, Y.K. Risk of clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am. J. Gastroenterol. 2012; 107:1011–1019.
34. Deshpande, A.; Pasupuleti, V.; Thota, P.; Pant, C.; Mapara, S.; Hassan, S.; Rolston, D.D.; Sferra, T.J.; Hernandez, A.V. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis. J. Gastroenterol. Hepatol. 2013, 28, 235–242.
35. Haigh, C.R.; Attwood, S.E.; Thompson, D.G.; Jankowski, J.A.; Kirton, C.M.; Pritchard, D.M.; Varro, A.; Dimaline, R. Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor. Gastroenterology 2003, 124, 615–625.
36. Gilard, M.; Arnaud, B.; Le Gal, G.; Abgrall, J.F.; Boschat, J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost. 2006; 4:2508–2509.
37. Ghebremariam, Y.T.; Lee, J.C.; LePendu, P.; Erlanson, D.A.; Slaviero, A.; Shah, N.H.; Leiper, J.M.; Cooke, J.P. Response to letters regarding article, “unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine”. Circulation 2014; 129:e428.
38. Merwat, S.N.; Spechler, S.J. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am. J. Gastroenterol. 2009; 104:1897–1902.



How to Cite

Khan, M. S., Singh, V., & Arora, P. (2021). Peptic Ulcer Disease (PUD): An overview of the History, Risk factors, Symptoms, Diagnosis Considerations and Conventional Management. Asian Journal of Pharmaceutical Research and Development, 9(5), 111–114.